BIOMAT Database Logo BIOMAT Database Logo

Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals. 2013

Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
Department of Pathology, New York University School of Medicine, New York, NY 10016, USA.

One approach to the development of an HIV vaccine is to design a protein template which can present gp120 epitopes inducing cross-neutralizing antibodies. To select a V3 sequence for immunogen design, we compared the neutralizing activities of 18 anti-V3 monoclonal antibodies (mAbs) derived from Cameroonian and Indian individuals infected with clade AG and C, respectively. It was found that V3 mAbs from the Cameroonian patients were significantly more cross-neutralizing than those from India. Interestingly, superior neutralizing activity of Cameroonian mAbs was also observed among the nine VH5-51/VL lambda genes encoding V3 mAbs which mediate a similar mode of recognition. This correlated with higher relative binding affinity to a variety of gp120s and increased mutation rates in V3 mAbs from Cameroon. These results suggest that clade C V3 is probably weakly immunogenic and that the V3 sequence of CRF02_AG viruses can serve as a plausible template for vaccine immunogen design.

UI MeSH Term Description Entries
D007194 India A country in southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Burma and Pakistan. The capitol is New Delhi. Republic of India
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D002163 Cameroon A republic in central Africa lying east of CHAD and the CENTRAL AFRICAN REPUBLIC and west of NIGERIA. The capital is Yaounde. Republic of Cameron,Cameroons,United Republic of Cameroon
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015699 HIV Envelope Protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. Envelope Glycoprotein gp120, HIV,HTLV-III gp120,env Protein gp120, HIV,gp120(HIV),HIV Envelope Glycoprotein gp120,gp120 Envelope Glycoprotein, HIV,HTLV III gp120,gp120, HTLV-III

Related Publications

Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.
July 2006, Journal of virology,
Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
Human Anti-HIV-1 gp120 Monoclonal Antibodies with Neutralizing Activity Cloned from Humanized Mice Infected with HIV-1.
February 2019, Journal of immunology (Baltimore, Md. : 1950),
Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
Correlation between anti-V3 peptide and neutralizing antibodies in plasma from HIV-1 infected individuals resident in Brazil.
January 1994, Memorias do Instituto Oswaldo Cruz,
Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
November 2004, AIDS research and human retroviruses,
Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.
April 2010, PloS one,
Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120.
October 1990, AIDS (London, England),
Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
September 2012, Virology journal,
Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.
November 2015, AIDS research and human retroviruses,
Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.
October 2011, Journal of virology,
Raiees Andrabi, and Constance Williams, and Xiao-Hong Wang, and Liuzhe Li, and Alok K Choudhary, and Naveet Wig, and Ashutosh Biswas, and Kalpana Luthra, and Arthur Nadas, and Michael S Seaman, and Phillipe Nyambi, and Susan Zolla-Pazner, and Miroslaw K Gorny
Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.
July 2006, Journal of virology,
Copied contents to your clipboard!